• Cy3 Goat Anti-Human IgG (H+L) Antibody: Precision in Immunoa

  2026-06-30

  The Cy3 Goat Anti-Human IgG (H+L) Antibody stands out for its robust signal amplification and versatility across immunofluorescence, IHC, flow cytometry, and ELISA workflows. With high specificity and minimal cross-reactivity, it empowers advanced human IgG detection in translational and clinical research.

• Tetraethylammonium Chloride: Optimizing K+ Channel Blockade

  2026-06-29

  Tetraethylammonium chloride stands out as a robust, dual-site K+ channel blocker for probing ion conduction and vascular modulation. This article details experimental workflows, protocol refinements, and troubleshooting strategies that leverage TEAC’s unique properties, with insights drawn from both foundational and cutting-edge studies.

• CD44-Driven Metabolic Rewiring in IDH-Mutant AML: New Insigh

  2026-06-29

  This study demonstrates that CD44-mediated metabolic rewiring is essential for sustaining pathogenic 2-hydroxyglutarate production in IDH-mutant acute myeloid leukemia (AML). Targeting this pathway, in combination with IDH2 inhibition, reveals a novel therapeutic vulnerability with significant implications for overcoming resistance in AML research.

• Cannabidiol Modulates Orofacial Inflammatory Pain Pathways

  2026-06-28

  This study provides detailed mechanistic evidence that cannabidiol (CBD) alleviates both sensory and affective aspects of orofacial inflammatory pain through coordinated peripheral and central endocannabinoid mechanisms. The findings highlight CBD’s multi-dimensional efficacy and translational potential for pain states with emotional comorbidities.

• Acetylation-Dependent Spliceosome Modulation in HCC Therapy

  2026-06-27

  This study elucidates how acetylation of the spliceosome core component SmD2 regulates alternative splicing and DNA damage response in hepatocellular carcinoma (HCC). By revealing the interplay between SmD2 acetylation, HDAC2 activity, and response to PARP inhibitors, the research highlights new therapeutic strategies for HCC involving HDAC and PARP inhibition.

• Bay 11-7821 (BAY 11-7082): Applied Workflows for NF-κB Pathw

  2026-06-26

  Bay 11-7821 (BAY 11-7082) is a selective IKK inhibitor that enables precise dissection of NF-κB signaling, inflammasome activation, and apoptosis regulation. Discover stepwise protocols, troubleshooting strategies, and the latest advances in inflammatory signaling pathway research that leverage this compound’s unique properties.

• DAPI Solution (1 mg/mL): Applied Workflows for Nuclear Visua

  2026-06-26

  DAPI Solution (1 mg/mL) from APExBIO delivers precise, reproducible nuclear staining, empowering apoptosis detection and viability assessment even in challenging samples. This guide translates current research and real-world protocols into actionable steps, spotlighting troubleshooting and advanced application strategies.

• Hypoxia-Induced Cognitive Impairment: Choroid Plexus and AMP

  2026-06-25

  This study reveals how hypoxic exposure disrupts cognitive function in mice through choroid plexus barrier impairment, driven by M1 macrophage polarization and aberrant AMPK pathway signaling. The findings highlight mechanistic links between oxygen deprivation, immune modulation, and central nervous system integrity, providing new directions for targeted research.

• Early Life Adversity Impairs Innate Defense via Oxytocin Cir

  2026-06-25

  Tan et al. reveal that early life adversity (ELA) disrupts visually evoked innate defensive behaviors in mice through impaired oxytocin signaling within the superior colliculus. This mechanistic work advances our understanding of how early social deprivation can impact neurobiological circuits governing fear responses, highlighting new targets for neurobehavioral intervention.

• AR and ARv7 Drive TNBC Progression: EPI-001 Blocks Metastati

  2026-06-24

  This study investigates the prognostic impact of androgen receptor (AR) and its splice variant ARv7 in triple-negative breast cancer (TNBC), revealing their association with poor outcomes and metastasis. Mechanistic experiments in TNBC cells show that EPI-001, an androgen receptor N-terminal domain inhibitor, modulates key metastatic and EMT regulators, highlighting new research directions for AR-driven TNBC.

• Milk-Derived Extracellular Vesicle Uptake in Piglet ISC Orga

  2026-06-23

  This study rigorously dissects the mechanisms by which milk-derived extracellular vesicles (MEV) interact with and are internalized by physiologically relevant porcine intestinal stem cell (ISC)–based organoid models. By demonstrating region- and polarity-specific uptake and the modulation of stemness and differentiation gene expression, the research provides new methodological and conceptual frameworks for studying intestinal physiology and vesicle trafficking.

• Resibufogenin Blocks NLRP3 Inflammasome to Alleviate Atheros

  2026-06-23

  A recent study demonstrates that resibufogenin (RBG) protects against atherosclerosis in ApoE-/- mice by specifically inhibiting NLRP3 inflammasome assembly. The work identifies a distinct molecular interaction and highlights implications for inflammation-driven cardiovascular disease interventions.

• Caspase-8 Fluorometric Assay Kit: Applied Workflows & Insigh

  2026-06-22

  Unlock precise caspase activity measurement with the Caspase-8 Fluorometric Assay Kit, a robust tool for apoptosis research and neurodegenerative disease models. This article delivers actionable protocol enhancements, advanced use-cases, and troubleshooting strategies, all grounded in the latest mechanistic findings.

• JNJ-10198409: Potent Platelet-Derived Growth Factor Receptor

  2026-06-22

  JNJ-10198409 is a highly potent platelet-derived growth factor receptor inhibitor that blocks PDGF-BB-driven signaling and cell proliferation. Its nanomolar IC50 and robust antiangiogenic effects make it a key compound for cancer biology and fibrotic disorder research. The compound enables reproducible, targeted suppression of tumor growth and angiogenesis in translational workflows.

• LY364947: Advancing Translational TGF-β Inhibition in EMT Re

  2026-06-21

  This article provides a mechanistic and strategic perspective on LY364947, a selective TGF-β type I receptor kinase inhibitor, emphasizing its pivotal role in epithelial-mesenchymal transition (EMT) research and translational modeling. Integrating recent evidence on pathway crosstalk and competitive strategies, we offer actionable guidance for researchers seeking to optimize the use of LY364947 in complex disease models, surpassing conventional product narratives.

437 records 12/30 page Previous Next First page 上5页 1112131415 下5页 Last page